Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Vasculitis 1Prostatic Neoplasms 1Neoplasm Metastasis 1Metabolic Syndrome 1Lung Neoplasms 1Inflammation 1Granulomatosis with Polyangiitis 1Bone Neoplasms 1Arthritis, Juvenile 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 5pembrolizumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Docetaxel 4Gemcitabine 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cemiplimab 2auricularum 2Specimen Handling 2Ramucirumab 2Radiotherapy 2Leucovorin 2Erlotinib Hydrochloride 2Drug Therapy 2Calcium Dobesilate 2pertuzumab 1oblimersen 1maimendongtang 1endostar protein 1cyclopropapyrroloindole 1cediranib 1aumolertinib 1anamorelin 1Vitamin B 12 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Etanercept × Clear all
NCT00127387 2012-06-26

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

The University of Texas Health Science Center at San Antonio

Phase 2/3 Terminated
54 enrolled
GenitourinarySarcomaThoracic

Bone Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡